MDS | Tumor

CURE’s myelodysplastic syndrome (MDS) page is an extensive resource of cancer information featuring the latest myelodysplastic syndrome news, expert oncologist insights on the latest cancer treatments, oncology research, advocacy efforts, and medical data on MDS.

Cancer Taught Me to Make the Best of Everything

December 13th 2024, 6:00pm

Article

As a survivor of MDS, I’ve learned to make the best of every day and to be thankful for life. Sometimes this means avoiding others who are less grateful.

Venclexta Plus Mavenclad Boosts Response Rates in AML, MDS

December 10th 2024, 2:05pm

Article

The Venclexta-based regimen improved complete response rates in patients with acute myeloid leukemia and myelodysplastic syndromes.

Smoking May Be Linked With Genetic Mutations, Progression Risk in MDS

December 7th 2024, 7:28pm

Article

Results from the study also showed the potential association between smoking, disease progression and survival in patients with myelodysplastic syndromes.

FDA Grants Fast Track Designation to R289 in Lower-Risk MDS

December 5th 2024, 2:00pm

Article

The novel treatment is being evaluated for patients with previously treated transfusion-dependent lower-risk myelodysplastic syndrome.

Donor Lymphocyte Infusion May Improve Survival in R/R MDS

November 20th 2024, 8:00pm

Article

Patients with relapsed or refractory MDS may experience improved overall survival with DLI, depending on certain prognostic factors.

Venclexta Regimen Beneficial for Patients with AML and MDS

November 19th 2024, 8:00pm

Article

Researchers have found an overall survival benefit and manageable safety profile with Venclexta for patients with AML and MDS.

Trial for Patients With High-Risk MDS Misses Goal, Discontinues Study

November 18th 2024, 10:00pm

Article

A trial evaluating the tamibarotene-Vidaza combination in certain patients with newly diagnosed high-risk MDS will be discontinued.

Taking Time to ‘Smell the Roses’

November 14th 2024, 6:00pm

Article

I spent my life racing against time, until my cancer diagnosis forced me to hit the brakes.

GVHD Prophylaxis Using PTCY Remains Valid Treatment Option in MDS

November 8th 2024, 8:00pm

Article

Graft-versus-host disease prophylaxis using posttransplant cyclophosphamide remains a valid option for patients with myelodysplastic syndromes.

Reblozyl May Be ‘The Standard of Care’ Now in Lower-Risk MDS, Anemia

September 24th 2024, 3:00pm

Article

An expert discussed the findings of the COMMANDS trial evaluating Reblozyl’s role in red blood cell transfusion independence for patients with MDS.